In this regard, our observation of enhanced antitumor immunity and tumor growth control upon Foxp3 degradation in the absence of severe adverse effects typically observed upon wholesale Treg cell ablation in experimental models of cancer45–55 offers a novel strategy for immunotherapy of tumors featuring highly activated and proliferative Treg cells. This evidence concerns the gene FOXP3 and neoplasm.